Business Development Manager
About the job
- A Master degree in Business or equivalent is required.
- Experience in licensing, business development, or merger and acquisition project coordination is required.
- International experience is required, preferably in the pharmaceutical or health sector.
- Exposure to and a good understanding of business and financial cases is required.
- The role requires autonomy, dynamism, problem-solving ability, an entrepreneurial mindset, and a team-player mindset.
- The role requires the ability to work within a lean organization.
- The role requires humility and adaptability.
- Excellent communication, presentation, and organizational skills are required.
- The ability to manage multiple projects and stakeholders is required.
- Fluent English is mandatory; French is an advantage.
- Support and assist the Chief Commercial & Business Development Officer in coordinating global business development opportunities, both internally and externally.
- Assist and deputize, when necessary, with contract negotiations, business development forums, scouting activities, and company meetings.
- Interact with internal corporate departments, including Medico Marketing, Competitive Intelligence, Regulatory, Supply Chain, and Finance, as well as global commercial team representatives such as Country Managers and B2B Partners.
- Scout and identify business development opportunities, with a focus on in-licensing and co-marketing, within the company’s commercialization strategy.
- Work with Portfolio Development to maintain and coordinate databases for business development and licensing and interdepartmental strategic initiatives and projects.
- Coordinate critical steps in the business development value chain, including confidentiality agreements, initial terms, IQVIA and Competitive Intelligence data, business plans, and due diligence data rooms.
- Assist and deputize the Chief Commercial & Business Development Officer in conferences, business development forums, and third-party company discussions, including follow-up actions.
- Collaborate hands-on with corporate departments on business development projects.
- Follow up proactively with the Chief Operating Officer and Finance to ensure the timely and qualitative availability of commercial business cases.
- Follow up on and align activities with predefined departmental and corporate priorities.
- Assist with department budget preparation and monthly reporting requirements.
- International experience in the pharmaceutical or health sector.
- French language skills.
About the company
ArchiMed is a private equity firm focused on healthcare investment. It backs growth-stage companies in Medtech, Biopharma, and Health & Care services, taking majority or minority stakes to help build integrated global leaders. Its approach combines sector-focused expertise with active buy-and-build strategies and notable funds like MED Platform II to support international expansion of portfolio companies. The goal is to generate attractive investor returns by creating globally competitive healthcare platforms and exiting them at a premium.
Company Size
N/A
Company Stage
N/A
Total Funding
$69.3M
Headquarters
Lyon, France
Founded
2014
Get referred to ARCHIMED
See people who can refer or advise you
Simplify's Take
What believers are saying
- Esperion’s July 13, 2026 take-private adds cardiometabolic cash flows and delisting upside.
- Stago generated €550 million revenue in 2025 across 115 countries, with recurring reagent demand.
- Renata Medical’s August 19, 2026 Series D shows ARCHIMED still funds growth-stage innovation.
What critics are saying
- Esperion’s $100 million CVR pays only if 2027-2030 sales milestones hit.
- Ademi LLP’s May 1, 2026 fairness probe signals shareholder litigation risk around Esperion.
- If healthcare M&A shuts, ARCHIMED’s fees and carry depend on paper marks.
What makes ARCHIMED unique
- ARCHIMED’s healthcare-only focus spans diagnostics, biopharma, medtech, and services across continents.
- Stago is the only pure-play hemostasis platform, giving ARCHIMED a defensible diagnostics anchor.
- MED IV closed September 9, 2026 at €1.5 billion, proving fundraising power.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Vision Insurance
Dental Insurance
Paid Vacation
Paid Holidays
Commuter Benefits
Meal Benefits
Company News
Standard BioTools announces agreement to sell Microfluidics business to ARCHIMED. Key Takeaway: Standard BioTools Inc. has announced a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The transaction is expected to close in about 30 days, pending customary conditions. CEO Michael Egholm expressed optimism about the future growth and innovation of the business under ARCHIMED's ownership. Market sentiment analysis. Positive factors. * ARCHIMED brings expertise and resources to support growth. * The sale is seen as a strong outcome for employees and customers. * Standard BioTools is executing its strategic actions effectively. Concerns & Risks. * The sale is subject to customary closing conditions. * There are risks related to the timely completion of the sale. * Potential competing offers could impact the transaction. BOSTON, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) - Standard BioTools Inc. (NASDAQ: LAB) ("Standard BioTools" or the "Company") today announced it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED ("ARCHIMED"), a leading investment firm focused exclusively on healthcare industries. Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools, said, "ARCHIMED brings deep healthcare and life sciences expertise, a strong understanding of the market and the resources to support the business' next chapter. This is a strong outcome for our employees and our customers, and we believe the business will continue to grow and innovate under new ownership. This transaction marks another important step in the strategic actions we laid out for Standard BioTools and our shareholders." The transaction is expected to close in approximately 30 days, subject to customary closing conditions. Until closing, the Microfluidics business will continue to operate as part of Standard BioTools. About Standard BioTools Inc. Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Learn more at standardbio.com or connect with BiopharmaWatch on X, Facebook(R), LinkedIn, and YouTube(TM). For Research Use Only. Not for use in diagnostic procedures. Limited Use Label License and other terms may apply: standardbio.com/legal/notices. Trademarks: standardbio.com/legal/terms-and-conditions/. Forward-Looking statements. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the disposition of the Microfluidics business and the expected outcome, timing and benefits of such disposition. The words "strong," "continue," "grow," "innovate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks, uncertainties, and assumptions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: (i) the risk that the sale of the Microfluidics business may not be completed in a timely manner or at all; (ii) the possibility that any or all of the various conditions to the consummation of the sale of the Microfluidics business may not be satisfied or waived; (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement relating to the sale of the Microfluidics business, including in circumstances that would require Standard BioTools to pay a termination fee or other expenses; and (iv) the possibility that competing offers or acquisition proposals will be made with respect to the Microfluidics business. For information regarding other related risks, see the "Risk Factors" section of Standard BioTools' Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on March 16, 2026, Standard BioTools' most recent Quarterly Report on Form 10-Q and Standard BioTools' other filings with the SEC. Should any of these risks or uncertainties materialize, actual results could differ materially from expectations. These forward-looking statements speak only as of the date hereof. Standard BioTools does not assume any obligation to, and does not currently intend to, update any such forward-looking statements except as may be required by law. Additional information and where to find it. This press release may be deemed to be solicitation material in respect of the proposed transactions involving Standard BioTools and Treeline Biosciences, Inc. ("Treeline") and/or Standard BioTools' sale of its Mass Cytometry business to Element Biosystems, LLC ("Element"). In connection with the Treeline transaction and related stockholder vote, Standard BioTools has filed with the SEC a registration statement on Form S-4 on July 20, 2026 that included a preliminary proxy statement and a preliminary prospectus of Standard BioTools, and that may be amended or supplemented from time to time. This communication is not a substitute for the preliminary proxy statement/preliminary prospectus or any other document that Standard BioTools may file with the SEC or send to its stockholders in connection with the proposed transactions. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. Any definitive proxy statement/prospectus (if and when available) will be mailed to stockholders of Standard BioTools. INVESTORS AND STOCKHOLDERS OF STANDARD BIOTOOLS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS, SUPPLEMENTS AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN) AND OTHER RELEVANT MATERIALS FILED OR TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE MAKING ANY VOTING DECISION WITH RESPECT TO THE PROPOSED TRANSACTIONS BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT STANDARD BIOTOOLS, TREELINE, ELEMENT AND THE PROPOSED TRANSACTIONS. Copies of the materials filed or to be filed by Standard BioTools with the SEC may be obtained free of charge on Standard BioTools' Investor Relations website at https://investors.standardbio.com or by contacting Standard BioTools' Investor Relations department at [email protected]. In addition, all of those materials will be available at no charge on the SEC's website at www.sec.gov. Participants in the solicitation. Standard BioTools, Treeline and certain of their respective directors, executive officers, other members of management and employees may be deemed to be participants in the solicitation of proxies of Standard BioTools stockholders in connection with the proposed transactions under SEC rules. Investors and stockholders may obtain more detailed information regarding the names, affiliations and interests of Standard BioTools' executive officers and directors who may, under SEC rules, be deemed participants in the solicitation by reading Standard BioTools' proxy statement for its 2026 annual meeting of stockholders (including under the headings "Management and Corporate Governance," "Executive Officer and Director Compensation," "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters," "Executive Compensation" and "Certain Relationships and Related Transactions, and Director Independence"), its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and Standard BioTools' other filings with the SEC. Information regarding Treeline's directors and executive officers who may be deemed participants in the solicitation is contained in the registration statement on Form S-4 filed by Standard BioTools. These documents are or will be available free of charge at the SEC's website at www.sec.gov or by going to Standard BioTools' Investor Relations website at http://investors.standardbio.com or contacting Standard BioTools' Investor Relations department at [email protected]. Standard BioTools: Media: dan moore / nick lamplough / tali epstein collected strategies [email protected]. Frequently asked questions. Who is acquiring Standard BioTools' Microfluidics business? ARCHIMED, a healthcare-focused investment firm, is acquiring the Microfluidics business. When is the sale of the Microfluidics business expected to close? The sale is expected to close in approximately 30 days, pending customary conditions. What did the CEO of Standard BioTools say about the sale? CEO Michael Egholm stated that the sale is a strong outcome for employees and customers. What are the risks associated with the sale? Risks include potential delays in closing and competing offers for the Microfluidics business.
Renata Medical closes $25M Series D financing led by global healthcare investment firm ARCHIMED to accelerate commercialization and development of pediatric cardiovascular technologies. August 19, 2026 los angeles biotechnology network news los angeles biotech news comments off on Renata Medical closes $25M Series D financing led by global healthcare investment firm ARCHIMED to accelerate commercialization and development of pediatric cardiovascular technologies. NEWPORT BEACH, Calif., Aug. 19, 2026 /PRNewswire/ - Renata Medical, a privately held medical technology company dedicated to transforming care for children with congenital heart disease (CHD), today announced the close of a $25 million Series D financing round. The round was led by...
IRAB, founded in 2016 and headquartered in Barcelona, develops and produces PET radiopharmaceuticals for clinical diagnosis, clinical trials and biomedical research.
Esperion Therapeutics has agreed to be acquired by healthcare-focused investment firm ARCHIMED in a deal valued at up to approximately $1.1 billion in total equity value. Under the agreement, Esperion shareholders will receive $3.16 per share in cash at closing, representing a 58% premium to the 30 April closing price, plus rights to up to $100 million in aggregate contingent milestone payments. The milestone payments are tied to future net sales performance of products containing bempedoic acid and bumetanide through 2030. Esperion's board has unanimously approved the transaction, which is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals. Following completion, Esperion will become privately held and delist from Nasdaq. Pharmakon Advisors will provide debt financing for the transaction.
ARCHIMED Diagnostics, along with minority investor La Caisse, acquires Stago, a global leader in blood coagulation analysis. PR Newswire Today at 5:34am PDT - Working with Stago management, ARCHIMED aims to expand sales and profits by building on gold-standard products in both developed and developing nations MONTRÉAL, April 29, 2026 /CNW/ - ARCHIMED Diagnostics - the Diagnostics team of global private equity healthcare specialist ARCHIMED - has purchased alongside global investment group La Caisse (formerly CDPQ), Stago, a world leader for the analysis of blood coagulation issues (hemostasis). Stago develops and manufactures hemostasis equipment and reagents. It has unique expertise and a track record of innovation in this specialty. Stago is held through ARCHIMED's MED Platform II fund and was purchased from the founding Viret family by the Diagnostics team through an unspecified mix of equity and unitranche debt. Stago sells its products in 115 countries and posted revenues of €550 million in 2025. Based in Asnières-sur-Seine (greater Paris), Stago was founded in 1945 and is the only pure-play hemostasis analysis company in the world. Stago's leadership team is taking a minority stake as part of the deal. "In addition to financial muscle, ARCHIMED and La Caisse have the operational sophistication and discretion to help us grow at a pivotal moment in our company's history," says incumbent Stago CEO Jean-Claude Piel, who retires from his post, becoming Chief of the Scientific and Technology Monitoring Committee. "ARCHIMED's diagnostics expertise is key for accelerating the efficient rollout of a major, new generation of Stago products," says Philippe Barroux, Stago's CEO-elect. Barroux, a 38-year Stago veteran, is currently CEO of operations in North America and China. "This partnership is all about reigniting innovation at Stago." ARCHIMED has made a total of eight diagnostics acquisitions, exiting two: Diesse, which became a pioneer in the development of cutting-edge systems for diagnosing inflammatory diseases and immune disorders in partnership with ARCHIMED; and Eurolyser, a point-of-care testing specialist, which saw profits rise more than two-fold and sales growth accelerate from the high single-digits to 25 percent annually during three years of ARCHIMED ownership. "Our aim is to provide Stago with the resources it needs to accelerate global growth and to reinforce its leading position as a pure player with unrivalled expertise," says ARCHIMED Managing Partner Vincent Guillaumot. "Stago has a pipeline of innovative products that should allow its revenues and profits to grow well above industry averages," adds ARCHIMED Partner Antoine Faguer. "Stago is a recognized leader in blood coagulation analysis, operating in a segment we know well, and serving a mission-critical role in medical diagnostics. Our investment alongside ARCHIMED reflects the value we place on partnerships and businesses with strong fundamentals," said Martin Longchamps, Executive Vice-President and Head of Private Equity and Private Credit at La Caisse. Working closely with Stago management, ARCHIMED will deploy its MedValue template - ARCHIMED's levers for accelerating the growth of partnering companies via internationalization (often including bolt-on acquisitions), innovation and product range expansion. Diagnostics is a primary investment sector for ARCHIMED, and one of the seven major sectors mapped through ARCHIMED's MedSeg, its proprietary sector analysis tool covering 430 sub-segments of the global health industry. For the acquisition of Stago, ARCHIMED also deployed MedDiscover, a proprietary set of tools and processes permitting ARCHIMED to identify and effectively engage with leading companies operating in ARCHIMED's prioritized sub-sectors. Stago is MED Platform II's 10th investment. All of MED Platform II's investments have been first-time leveraged buyouts for the companies acquired. MED Platform II, more than two times oversubscribed, closed on €3.5 billion in June, 2023. According to Preqin data, the fund is a top quartile performer for its vintage year as are all ARCHIMED funds. After the Stago transaction, MED Platform II is some 70 percent invested. ABOUT ARCHIMED www.archimed.group - With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Services, and MedTech. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €9 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation. ABOUT LA CAISSE At La Caisse, formerly CDPQ, Cranbrook Townsman has invested for 60 years with a dual mandate: generate optimal long-term returns for its 48 depositors, who represent over 6 million Quebecers, and contribute to Québec's economic development. As a global investment group, Cranbrook Townsman is active in the major financial markets, private equity, infrastructure, real estate and private credit. As at December 31, 2025, La Caisse's net assets totalled CAD 517 billion. For more information, visit lacaisse.com or consult its LinkedIn or Instagram pages. La Caisse is a registered trademark of Caisse de dépôt et placement du Québec that is protected in Canada and other jurisdictions and licensed for use by its subsidiaries. La Caisse CONRAD HARRINGTON Senior Director - International Media Relations + 1 514 847-5493 [email protected] International David Lanchner [email protected] +33 (0) 6 33 43 50 76 +1 646 302 2435 SOURCE La Caisse This is a paid placement. For further inquiries, please contact PR Newswire directly.